CA2744307A1 - Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission - Google Patents

Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission Download PDF

Info

Publication number
CA2744307A1
CA2744307A1 CA2744307A CA2744307A CA2744307A1 CA 2744307 A1 CA2744307 A1 CA 2744307A1 CA 2744307 A CA2744307 A CA 2744307A CA 2744307 A CA2744307 A CA 2744307A CA 2744307 A1 CA2744307 A1 CA 2744307A1
Authority
CA
Canada
Prior art keywords
stereoisomers
disorders
mixture
phenyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2744307A
Other languages
English (en)
French (fr)
Inventor
Clas Sonesson
Lars Swanson
Fredrik Pettersson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NSAB Filial af Neurosearch Sweden AB
Original Assignee
NSAB Filial af Neurosearch Sweden AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NSAB Filial af Neurosearch Sweden AB filed Critical NSAB Filial af Neurosearch Sweden AB
Publication of CA2744307A1 publication Critical patent/CA2744307A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2744307A 2008-11-24 2009-11-24 Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission Abandoned CA2744307A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200801656 2008-11-24
DKPA200801656 2008-11-24
US11781808P 2008-11-25 2008-11-25
US61/117,818 2008-11-25
PCT/EP2009/065675 WO2010058017A1 (en) 2008-11-24 2009-11-24 Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission

Publications (1)

Publication Number Publication Date
CA2744307A1 true CA2744307A1 (en) 2010-05-27

Family

ID=41649970

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2744307A Abandoned CA2744307A1 (en) 2008-11-24 2009-11-24 Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission

Country Status (8)

Country Link
US (1) US8586572B2 (enExample)
EP (1) EP2367785B1 (enExample)
JP (1) JP5621087B2 (enExample)
CN (1) CN102224135A (enExample)
AU (1) AU2009317155A1 (enExample)
CA (1) CA2744307A1 (enExample)
MX (1) MX2011005034A (enExample)
WO (1) WO2010058017A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5716202B2 (ja) 2008-11-24 2015-05-13 インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー 皮質のカテコールアミン作動性神経伝達のモジュレーターとしての３−フェニル−３−メトキシピロリジン誘導体
EP3297987B1 (en) * 2015-05-20 2019-05-15 Integrative Research Laboratories Sweden AB Novel azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission
ES2962865T3 (es) 2016-11-18 2024-03-21 Integrative Res Laboratories Sweden Ab Nuevos derivados de azetidina útiles como moduladores de la neurotransmisión catecolaminérgica cortical

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3668196A (en) * 1965-10-22 1972-06-06 Lilly Co Eli 3-azetidinols
US3481920A (en) * 1965-10-22 1969-12-02 Lilly Co Eli Azetidinones
US3822252A (en) 1968-06-28 1974-07-02 Schering Corp 3-azetidinols
CH524598A (de) * 1968-06-28 1972-06-30 Scherico Ltd Verfahren zur Herstellung neuer Azetidinderivate
GB1236078A (en) * 1968-07-04 1971-06-16 Beecham Group Ltd Substituted azetidinols
US3494964A (en) 1969-01-13 1970-02-10 Lilly Co Eli Alpha-halo-alpha-amino ketones
WO1999037613A1 (en) * 1998-01-23 1999-07-29 Vernalis Research Limited Azetidinecarboxamide derivatives for treating cns disorders
GB9917384D0 (en) * 1999-07-23 1999-09-22 Cerebrus Ltd Chemical compounds-III
AU2002363236A1 (en) * 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
WO2005026146A1 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Azetidinyl quinolones as antibacterial agents
WO2005026153A1 (en) 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinazoline-2, 4-diones as antibacterial agents
ZA200603672B (en) * 2003-11-10 2007-09-26 Microbia Inc 4-biarylyl-1-phenylazetidin-2-ones
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
JP2008543828A (ja) * 2005-06-15 2008-12-04 ファイザー・リミテッド ドーパミン作動薬としての３−フェニルアゼチジン誘導体
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US8188301B2 (en) 2007-06-05 2012-05-29 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
DE602008006720D1 (de) 2007-06-05 2011-06-16 Nsab, Filial Af Neurosearch Sweden Ab Neue disubstituierte phenylpyrrolidine als modulatoren der kortikalen katecholaminergen neurotransmission
WO2010058020A1 (en) 2008-11-24 2010-05-27 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Novel 1 -alkyl- 3 -hydroxy- 3 -phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
JP5716202B2 (ja) 2008-11-24 2015-05-13 インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー 皮質のカテコールアミン作動性神経伝達のモジュレーターとしての３−フェニル−３−メトキシピロリジン誘導体

Also Published As

Publication number Publication date
US20110281835A1 (en) 2011-11-17
EP2367785B1 (en) 2014-10-15
JP2012509860A (ja) 2012-04-26
CN102224135A (zh) 2011-10-19
EP2367785A1 (en) 2011-09-28
US8586572B2 (en) 2013-11-19
MX2011005034A (es) 2011-06-16
AU2009317155A1 (en) 2010-05-27
JP5621087B2 (ja) 2014-11-05
WO2010058017A1 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
US9035073B2 (en) 3-phenyl-3-methoxy-pyrrolidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
AU2012244867A1 (en) Novel modulators of cortical dopaminergic- and NMDA-receptor-mediated glutamatergic neurotransmission
US8492372B2 (en) Modulators of dopamine neurotransmission
EP2367786B1 (en) Novel 1 -alkyl- 3 -hydroxy- 3 -phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
EP2367785B1 (en) Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
WO2016185032A1 (en) Novel azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission
HK1162172A (en) Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
HK1162173B (en) 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20141125